Evidence map›Paper›PMID 35051443›Full record

ArticleJournal of virological methods2022

Use of the Ct difference between the Nucleocapside (N) and the Spike (S) or RNA-dependent RNA polymerase (RdRP) genes as a preliminary screening for SARS-CoV-2 variants with the Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay: Searching the N in Variants.

Mikel Urrutikoetxea-Gutierrez, Mª Carmen Nieto Toboso, Estibaliz Ugalde Zarraga, Mikele Macho Aizpurua, Jose Luis Díaz de Tuesta Del Arco

Open access · greenAbstract read
In one paragraph

Article in Journal of virological methods, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Mikel Urrutikoetxea-GutierrezClinical Microbiology Service, Basurto University Hospital, Spain; Microbiology and Infection Control Study Group, IIS Biocruces Bizkaia, Spain. Electronic address: mikel.j.urruti@gmail.com.
Mª Carmen Nieto TobosoClinical Microbiology Service, Basurto University Hospital, Spain; Microbiology and Infection Control Study Group, IIS Biocruces Bizkaia, Spain.
Estibaliz Ugalde ZarragaClinical Microbiology Service, Basurto University Hospital, Spain; Microbiology and Infection Control Study Group, IIS Biocruces Bizkaia, Spain.
Mikele Macho AizpuruaClinical Microbiology Service, Basurto University Hospital, Spain; Microbiology and Infection Control Study Group, IIS Biocruces Bizkaia, Spain.
Jose Luis Díaz de Tuesta Del ArcoClinical Microbiology Service, Basurto University Hospital, Spain; Microbiology and Infection Control Study Group, IIS Biocruces Bizkaia, Spain.
BioCruces Health research Institute · ESHospital de Basurto · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWith the rise of the different Variants of Concern (VOC) and Variants of Interest (VOI) in order to control the SARS-CoV-2 pandemic, strategies for accurately tracking these different variants have been developed. While most of these strategies rely heavily on specific PCRs targeting the characteristic mutations of some lineages, several approaches using the alterations at the cycle threshold (Ct) of different commercial PCR diagnostic tests have been described. The objective of this study is to analyse the use of the Ct difference at the Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay (Seegene, Korea) between the Nucleocapside (N) and the Spike (S) or RNA-dependent RNA polymerase (RdRP) genes as a preliminary screening for variant tracking.

methodsThe samples analysed with the Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay from 1

resultsThe mean ΔS and ΔRdRP were characteristic for Alpha and Delta. This difference was statistically significant. For Every analysed Variant the diagnostic test achieved a higher than 90% sensitivity with a noteworthy performance with the Omicron variant (97% sensitivity and 90% specificity).

conclusionsThe analysis of the Ct alterations at the Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay may be a suitable method for an early approach to SARS-CoV-2 variant assessment.

Indexed as

COVID-19SARS-CoV-2COVID-19 TestingHumansRNA-Dependent RNA PolymeraseRNA-Dependent RNA PolymeraseAlphaDeltaOmicronRT-PCRSARS-CoV-2Variants

Identifiers

PMID35051443
PMCPMC8763412
OpenAlexW4205841380

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.